EcoDrugPlus

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSAOCG00000001518
Gene Symbol: LOC111582761
3 Cross references
181 Possible Orthologues:

Vascular Endothelial Growth Factor A-A-Like

Ensembl ID : ENSAOCG00000021800
Gene Symbol: LOC111583272
3 Cross references
198 Possible Orthologues:

Vascular Endothelial Growth Factor Receptor 1-Like

Ensembl ID : ENSAOCG00000011809
Gene Symbol: LOC111572455
3 Cross references
199 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSAOCG00000009431
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSAOCG00000011299
Gene Symbol: LOC111565886
3 Cross references
394 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like

Ensembl ID : ENSAOCG00000021862
Gene Symbol: LOC111581582
3 Cross references
191 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1c-Like

Ensembl ID : ENSAOCG00000024251
Gene Symbol: LOC111571438
3 Cross references
215 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSAOCG00000010953
Gene Symbol: LOC111584413
2 Cross references
210 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSAOCG00000007319
Gene Symbol: LOC111571955
3 Cross references
212 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSAOCG00000011603
Gene Symbol: LOC111567032
3 Cross references
203 Possible Orthologues:

Voltage-Dependent N-Type Calcium Channel Subunit Alpha-1b-Like

Ensembl ID : ENSAOCG00000022568
Gene Symbol: LOC111580308
3 Cross references
211 Possible Orthologues:

Voltage-Dependent P/q-Type Calcium Channel Subunit Alpha-1a-Like

Ensembl ID : ENSAOCG00000010481
Gene Symbol: LOC111588675
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).